U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07385664) titled 'Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC' on May 20, 2025.
Brief Summary: This study was a single-arm, two-cohort, phase II trial aimed at evaluating the efficacy and safety of FAPI-PET/CT response for guiding the selection of neoadjuvant treatment modes after chemotherapy combined with immunotherapy.
Study Start Date: Jan. 28
Study Type: INTERVENTIONAL
Condition:
Resectable Esophageal Cancer
Intervention:
COMBINATION_PRODUCT: Neoadjuvant Chemoimmunotherapy or Concurrent Chemoradiotherapy
FAPI-PET/CT was carried out between days 15 and 22 after two cycles of chemoimmunotherapy. If the FAPI-PET/CT results ind...